Entecavir monohydrate(SQ 34676; BMS 200475) is a nucleoside analog that inhibits reverse transcription; entecavir is used to treat chronic hepatitis B.
IC50 value:
Target: HBV
Entecavir monohydrate is an oral antiviral drug used in the treatment of hepatitis B infection. Entecavir monohydrate is a nucleoside analog (more specifically, a guanine analogue) that inhibits reverse transcription, DNA replication and transcription in the viral replication process. Entecavir monohydrate is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). Entecavir monohydrate is also indicated for the treatment of chronic hepatitis B in adults with HIV/AIDS infection. However, Entecavir is not active against HIV.
Entecavir cumulative urinary excretion was statistically significant at 45 and 60min. CLR(4°C), CLR(37°C Control) and CLR(37°C Experiment) were 12.6, 27.6 and 36 (ml/min/kg), respectively. CLTS and TR rate (for PEPT2) were 25.3 and 9.4 (ml/min/kg). In vivo, the cumulative urinary excretion of entecavir had statistical significance at 3 and 4h with CLR(Control) and CLR(Experiment) values of 31 and 42 (ml/min/kg), respectively. The CLTS and TR rate (for PEPT2) were 32 and 11.6 (ml/min/kg), respectively.
indications: Hepatitis B virus infection
FDA Approved Date:   March 2005

Adefovir dipivoxil
Bicyclol
Clevudine
Entecavir
Helioxanthin
Helioxanthin 8-1
Merimepodib
Telbivudine